In this brief article, we present important Dupixent legal and medical information about T-cell lymphoma, which appears to be a Dupixent-related side effect. We start with some of the allegations contained in the lawsuits being filed against the pharmaceutical companies Regeneron Pharmaceuticals, … More
Main Navigation Menu
➤ About the Law Offices of Thomas J. Lamb
PRACTICE AREAS
➤ Asbestos and Mesothelioma Claims
➤ Benzene Cancer and Disease Claims
➤ Pharmaceutical Drug Injury Lawsuits
➤ Breast Implants Lymphoma Cancer Lawsuits
➤ Free Case Evaluation by Lawyer Tom Lamb
INFORMATION
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Our "Recent Articles" Archives
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent Articles
Chrysotile asbestos—the deadly consequences of a retreat from national bans
Many in the global clinical and research community reacted with horror to the June 18, 2025, news that the Trump administration was requesting that the US Environmental Protection Agency (US EPA) should “reconsider” the country’s ban on chrysotile asbestos. This ban had been previously enacted under … More
Dupixent Cancer Lawsuits: Legal and Medical Update
We are currently investigating possible Dupixent cancer lawsuits for patients who were diagnosed with a type of cutaneous T-cell lymphoma (CTCL), such as mycosis fungoides (MF) or Sézary syndrome, after they started using Dupixent. The Dupixent cancer lawsuits would be filed against the … More
Increased Risk of NAION Associated With Ozempic and Mounjaro
A 2025 medical study concluded that there is an increased risk of NAION associated with Ozempic and Mounjaro. In more detail, the researchers considered whether treatment with either Ozempic (semaglutide) or Mounjaro (tirzepatide) is associated with an increased risk of non-arteritic anterior … More
Prognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Background: Malignant peritoneal mesothelioma (MPM) is a rare but aggressive cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was the preferred choice for selected patients. The purpose of this study was to thoroughly examine the impact of the combined … More
Long Road to Identifying Peritoneal Mesothelioma: An Elusive Diagnosis
Peritoneal mesothelioma is a rare and aggressive malignancy [ of the peritoneum ] that often presents with non-specific abdominal symptoms such as ascites, leading to delayed diagnosis and treatment. It poses significant diagnostic challenges, especially in the absence of classical risk factors like … More